Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
LAT-8881 by Lateral Pharma for Radiculopathy: Likelihood of Approval
LAT-8881 is under clinical development by Lateral Pharma and currently in Phase I for Radiculopathy. According to GlobalData, Phase I...